Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mersana Therapeutics stock

Own Mersana Therapeutics stock in just a few minutes.

Mersana Therapeutics, Inc is a biotechnology business based in the US. Mersana Therapeutics shares (MRSN) are listed on the NASDAQ and all prices are listed in US Dollars. Mersana Therapeutics employs 110 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Mersana Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRSN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mersana Therapeutics share price

Use our graph to track the performance of MRSN stocks over time.

Mersana Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$7.66 - $29.09
50-day moving average $17.01
200-day moving average $20.46
Wall St. target price$26.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.12

Buy Mersana Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Mersana Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Mersana Therapeutics financials

Revenue TTM $828,000
Gross profit TTM $-66,208,000
Return on assets TTM -28.91%
Return on equity TTM -57.47%
Profit margin 0%
Book value $3.31
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Mersana Therapeutics shares

There are currently 9.8 million Mersana Therapeutics shares held short by investors – that's known as Mersana Therapeutics's "short interest". This figure is 13.8% up from 8.6 million last month.

There are a few different ways that this level of interest in shorting Mersana Therapeutics shares can be evaluated.

Mersana Therapeutics's "short interest ratio" (SIR)

Mersana Therapeutics's "short interest ratio" (SIR) is the quantity of Mersana Therapeutics shares currently shorted divided by the average quantity of Mersana Therapeutics shares traded daily (recently around 792423.50565428). Mersana Therapeutics's SIR currently stands at 12.38. In other words for every 100,000 Mersana Therapeutics shares traded daily on the market, roughly 12380 shares are currently held short.

However Mersana Therapeutics's short interest can also be evaluated against the total number of Mersana Therapeutics shares, or, against the total number of tradable Mersana Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mersana Therapeutics's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Mersana Therapeutics shares in existence, roughly 140 shares are currently held short) or 0.1767% of the tradable shares (for every 100,000 tradable Mersana Therapeutics shares, roughly 177 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Mersana Therapeutics.

Find out more about how you can short Mersana Therapeutics stock.

Mersana Therapeutics share dividends

We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.

Mersana Therapeutics share price volatility

Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $7.66 up to $29.09. A popular way to gauge a stock's volatility is its "beta".

MRSN.US volatility(beta: 2.48)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 2.4825. This would suggest that Mersana Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Mersana Therapeutics overview

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the development of antibody drug conjugates (ADC) for cancer patients with unmet need. The company develops XMT-1536, a Dolaflexin ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer and non-small cell lung cancer (NSCLC) adenocarcinoma; and XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumors, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. It also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. The company has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site